Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2013.275 | The effect of a health promotion program on health outcomes and health-promoting behavior of individuals with metabolic syndrome: a randomized controlled trial | Ms Lo Wai Sze |
| 2012.260 | Retrospective study of clinical features and etiopathogenesis of colonic marginal zone lymphoma | Dr LO Wing Ip Anthony |
| 2024.201 | The effects of occupational therapy home-based program for people with mild to moderate level of dementia and their caregivers: a randomized controlled trial |
Mr. LO Wing Tong 盧頴唐 |
| 2008.072 | The Relationship of Swimming Stroke and Shoulder Laxity among Elite College Swimmers - A Retrospective Cohort Study | DR LO Xina |
| 2017.526 | Feasibility of Same Day Discharge After Total Thyroidectomy | Dr. LO Xina |
| 2014.304 | Massively parallel sequencing of plasma nucleic acids for the assessment of preeclampsia | Prof Lo Yuk Ming Dennis |
| 2014.187 | Massively parallel sequencing of plasma nucleic acids for the assessment of stroke | Prof Lo Yuk Ming Dennis |
| 2009.410 | On the origin of the maternal age effect in trisomy 21 Down syndrome | Prof Lo Yuk Ming Dennis |
| 2012.077 | An Investigation into the Biology of Circulating Nucleic in Patients with Systemic Lupus Erythematosus by Next-Generation Sequencing | Prof Lo Yuk Ming Dennis |
| 2009.176 | A randomized study of prolonged pretreatment with gonadotrophin releasing hormone agonist (GnRHa) prior to frozen-thawed embryo transfer (FET) cycles in patients with endometriosis | Dr. Lok Ingrid Hung |
| 2016.417 | Visual outcome and refractive status in first 3 years of age in laser-treated high risk pre-threshold Type 1 retinopathy of prematurity (ROP): A 6 year retrospective review in Hong Kong population a tertiary centre in Hong Kong |
Dr. LOK Julie Ying Ching 駱映晴 |
| 2015.167 | Evaluating effect of strabismus surgery on reading-related skills in Chinese school-aged children with intermittent exotropia and constant exotropia |
Dr. LOK Julie Ying Ching 駱映晴 |
| 2017.654 | Deep learning algorithm for the detection of of diabetic retinopathy and/or age-related macular degeneration in a Chinese population |
Dr. LOK Ka Hing 駱家慶 |
| 2019.468 | The prevalence of chromosomal abnormalities in fetuses with different degree of cerebral ventriculomegaly and the association of neurodevelopmental outcome after birth | Dr. LOK Wing Yi |
| 2024.038 | Deciphering the role of macrophage metabolic reprogramming in immunotherapy resistance of non-alcoholic steatohepatitis-hepatocellular carcinoma | Dr. LONG Xiaohang |
| 2021.495 | Reduction of Polypharmacy in Frail Elderly Patients in Hong Kong Using STOPPFrail Criteria |
Dr LOO Chi Wah 盧志華 |
| 2020.197 | Blood-based Technology for the Detection of Epidermal Growth Factor Receptor Exon 20 Insertion in Patients with Advanced Stage Lung Cancer | Dr. LOONG Herbert |
| 2016.625 | A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors |
Dr. LOONG Herbert 龍浩鋒 |
| 2016.164 | A PILOT RANDOMIZED OPEN-LABELED STUDY COMPARING A STRUCTURED TITRATION METHOD OF IMMEDIATE- AND SUSTAINED-RELEASE OXYCODONE VERSUS OPIOIDS TITRATION OF INVESTIGATORS’ CHOICE IN ADVANCED CANCER PATIENTS IN HONG KONG | Dr. LOONG Herbert |
| 2016.162 | A Feasibility Study Investigating the Presence of Intra- and Inter-tumoural Heterogeneity in Gastrointestinal Stromal Tumours and Its Potential Impact on Treatment Response, Monitoring and Patients’ Survival | Dr. LOONG Herbert |
| 2015.257 | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine |
Dr. LOONG Herbert 龍浩鋒 |
| 2016.165 | An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma |
Dr. LOONG Herbert 龍浩鋒 |
| 2014.457 | A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer | Prof. LOONG Herbert |
| 2015.632 | A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1) |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2015.155 | A multicenter randomized, open-label, phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2018.422 | A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.609 | A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF OZURIFTAMAB VEDOTIN (BA3021) ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Dr. LOONG Herbert H.F. |
| 2019.518 | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.585 | A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed following Definitive, Platinum-Based, Chemoradiation Therapy (PACIFIC 5) |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2020.515 | Determining Engrailed-2 (EN2) Concentration in Urine Samples for Clinical Development of a Urine Lateral Flow Assay for Screening Urinary Tract Cancers |
Dr. LOONG Herbert H.F. 龍浩鋒醫生 |
| 2019.541 | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.346 | Co-morbidities, healthcare utilization and survival outcomes of patients with soft-tissue and bone sarcomas in Hong Kong |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.652 | A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors | Dr. LOONG Herbert Ho Fung |
| 2019.493 | A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC) | Dr. LOONG Herbert Ho Fung |
| 2020.513 | A Pilot Study to Establish a Local Next-Generation Sequencing (NGS) Platform Enhanced with Artificial Intelligence (AI) For high Throughput Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.553 | A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.565 | A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.179 | A Phase 2 Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.523 | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.554 | A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2020.366 | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.375 | Prospective Molecular Profiling in Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.020 | A single-arm, open-label, phase 2 study of dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.056 | LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.198 | Clinical Application of a Personalized Circulating Tumour DNA (ctDNA) Assay for Early Detection of Cancer Relapse |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2019.524 | Bayer 20810 - A Phase 1/2 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: LOXO-EXT-17005 - A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers | Dr. LOONG Herbert Ho Fung |
| 2020.022 | Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous group of patients? |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2020.626 | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.658 | A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction |
Dr. LOONG Herbert Ho Fung 龍浩鋒 醫生 |
| 2019.386 | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms | Dr. LOONG Herbert Ho Fung |
Page 154 of 254.